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Abstract
Cell-derived microvesicles (MVs) are a recently discovered mechanism of cell-to-cell communication. Our previous data show
that MVs secreted by equine amniotic mesenchymal-derived cells (AMCs) are involved in downregulation of proinflammatory
genes in lipopolysaccharide-stressed equine tendon and endometrial cells. The aim of the present study was to evaluate whether
AMC-MVs contain selected microRNAs (miRNAs) involved in inflammation. Two pools of cells, derived from 3 amniotic
membranes each, and their respective MVs were collected. Small RNAs were extracted and deep sequenced, followed by
miRNA in silico detection. The analysis identified 1,285 miRNAs, which were quantified both in AMCs and MVs. Among these
miRNAs, 401 were classified as Equus caballus miRNAs, 257 were predicted by homology with other species (cow, sheep, and
goat), and 627 were novel candidate miRNAs. Moreover, 146 miRNAs differentially expressed (DE) in AMCs and MVs were
identified, 36 of which were known and the remaining were novel. Among the known DEmiRNAs, 17 showed higher expression
in MVs. Three of these were validated by real time polymerase chain reaction: eca-miR-26, eca-miR-146a, and eca-miR-223. Gene
ontology analysis of validated targets showed that the DE miRNAs in cells and MVs could be involved both in immune system
regulation by modulating interleukin signaling and in the inflammatory process. In conclusion, this study suggests a significant role
of AMCs in modulating immune response through cell–cell communication via MV-shuttling miRNAs.
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Introduction
In cell therapy, for many years, mesenchymal stromal cells
(MSCs) have been used for their action based on their abil-
ity to differentiate into reparative or replacement cell types,
enhance the nutrient supply, and improve the survival and
function of the endogenous cells via paracrine actions1–3.
Considering the inhospitable environment of the lesion, due
to the presence of inflammatory cells and molecules that
lead to a premature death of stem cells used in cell therapy4,
it is now suggested that paracrine signaling is mainly
involved in repair. Indeed, some studies revealed that cell
secretion alone, or conditioned medium (CM), without the
stem cells themselves, led to tissue repair in various con-
ditions that involve tissue/organ damage5–7. Each stem cell
type, depending on its very typical nature, can secrete dif-
ferent factors including small soluble molecules (neuro-
transmitters, chemokines, cytokines, and hormones) that
could behave in a paracrine or in an endocrine manner8.
However, some factors, such as nucleic acid, cannot span the
membranes freely and a vehicle should be involved to facilitate
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the crossing. Microvesicles (MVs), which are released by cells
into the extracellular environment9,10, have been supposed as
shuttles of the functional components for MSC paracrine
action. The MVs, or extracellular vesicles, are membrane-
bound vesicles that transfer molecules such as lipids, proteins,
and nucleic acids from one cell to another, thereby influencing
the recipient cell function11,12. The MVs are classified in shed-
ding vesicles, if released by budding of cell membrane, and
exosomes that form in multivesicular bodies are released by
exocytosis. These 2 kinds of MVs are also different in size: 30
to 120 nm for exosomes and 100 to 1,000 nm for shedding
vesicles10. The MVs have been studied in several biological
processes and are now characterized as novel mediators of
intercellular communication both in healthy systems and dur-
ing disease pathogenesis13. Their proregenerative role is
described in several models of tissue regeneration including
regeneration of the kidney10,14, heart15, liver16,17, and nervous
tissues18. Many other studies have been performed on the abil-
ity of MVs to carry information between cells, with the aim of
ameliorating a pathological situation. Some of these studies
demonstrated that MVs from different cell sources have immu-
nological properties, since they are able to differentially mod-
ulate T, B, and natural killer (NK) cell functions19.
Our research group tested the CM, derived from equine
amniotic mesenchymal cells (AMCs), in the treatment of
spontaneous tendon lesion in sport horses, showing angio-
genic and healing properties mediated by paracrine mechan-
isms6. These results overlap with those previously obtained
treating the same pathology with only AMCs20.
It is important to emphasize that the CM obtained by
amniotic membrane holds the same in vivo potential of
cells. On the contrary, bone marrow–derived cells and their
CM exert immunomodulatory potential only if the cells are
cultured in the presence of activating conditions21. This
increases the interest for the therapeutic potential of
amniotic-derived cells based on their paracrine effects and
on their released factors. Indeed, to understand the same
therapeutic effects in the absence of cells, Lange-Consiglio
et al.22 verified the presence and the type of MVs secreted
by AMCs and classified these MVs as shedding vesicles.
Then, they tested the action of AMC-MVs on tendon and
endometrial cells stressed in vitro by lipopolysaccharide
(LPS). They observed the incorporation of labeled MVs
within both cell lines, the downregulation of tumor necrosis
factor-a (TNF-a), interleukin 6 (IL-6), IL-1b, matrix metal-
loproteinase-1 (MMP-1), and MMP-13 genes and the
restoration of transforming growth factor-b (TGF-b)
expression22,23. Undoubtedly, MVs and their cargo play
key roles in these effects, but the exact mechanisms regard-
ing the interaction of MVs and the injured tissues need
further investigation. The main question to explain all these
data is “how do MVs act?” One of the most attractive
characteristics of MVs is their ability to transfer RNAs
(tRNAs) from one cell to another, thereby allowing the
transferred RNAs to affect the target cells. In recent years,
a remarkable finding demonstrated that MV-contained
mRNAs could be transferred in recipient cells and trans-
lated into proteins9,24. Furthermore, MVs containing RNAs
have been shown to be transferred from MSCs to injured
cells and to contribute to tissue recovery25. Additionally, in
2010, MVs were shown to transfer microRNAs (miRNAs)
between cells, and these miRNAs displayed RNA interfer-
ence effects in the recipient cells26–28. This means that MVs
may have a functional impact on the target cells through
miRNA delivery. The miRNAs are a group of small (21–24
nt) noncoding RNAs that function as posttranscriptional
regulators of gene expression by either triggering mRNA
cleavage or repressing translation29–31. Cantaluppi et al.14
reported that, in MVs derived from endothelial progenitor
cells, specific enrichment of mRNAs involved in cell pro-
liferation, transcription, and immune regulation was
detected, providing an example of selective uptake of RNA
species into MVs. The mechanism of mRNA and miRNA
compartmentalization within MVs has not been clarified;
however, it is possible that ribonucleoproteins, that mediate
the fate of RNAs within the cells, could be involved32. The
transfer of miRNAs by MVs could be important in tissue
regeneration; indeed, the positive effect of these MVs is
inhibited by the knockdown of Dicer, essential for miRNA
processing14. These data indicate an important and poten-
tial role of MVs-transferred miRNA in stimulating tissue
regeneration.
In this context, in addition to previous characterization of
AMC-derived MVs22, the aim of this study was to compara-
tively investigate the miRNA content in AMCs and their
MVs to assess if also in this cell line a compartmentalization
of miRNAs involved in anti-inflammatory processes exists.
Materials and Methods
Chemicals, cell culture media, and supplements were
obtained from Sigma (Milano, Italy) unless otherwise spec-
ified, and tissue culture dishes were purchased from Euro-
clone (Milano, Italy).
Tissue Collection and Cell Isolation
All procedures to collect allanto-amniotic membrane were
conducted following standard veterinary practice and in accor-
dance with 2010/63 European Union directive on animal pro-
tection and Italian Law (D.L. No. 116/1992). Allanto-amniotic
membranes were obtained at term from normal pregnancies of
6 mares and amniotic cells were obtained as described by
Lange-Consiglio et al.33 Briefly, the amniotic membrane was
stripped from the overlying allantois and cut into small pieces
(about 9 cm2 each) before starting the enzymatic digestion.
Then, amnion fragments were incubated for 9 min at 38.5 C
in phospate buffer saline (PBS) containing 2.4 U/mL dispase
(Becton Dickinson, Milan, Italy). After a resting period
(5–10 min) at room temperature in high-glucose Dulbecco’s
modified Eagle’s medium (HG-DMEM; EuroClone), supple-
mented with 10% heat inactivated fetal bovine serum (FBS)
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and 2 mM L-glutamine, the fragments were digested with
0.93 mg/mL collagenase type I and 20 mg/mL DNase (Roche,
Mannheim, Germany) for approximately 3 h at 38.5 C. The
amnion fragments were removed, and mobilized cells were
passed through a 100 mm cell strainer before being collected
by centrifugation at 200 g for 10 min. Cells cultures were
established in HG-DMEM supplemented with 10% FBS, peni-
cillin (100 UI/mL)-streptomycin (100 mg/mL), 0.25 mg/mL
amphotericin B, 2 mM L-glutamine, and 10 ng/mL epidermal
growth factor (EGF). Amniotic cells were cultured and
expanded to passage (P) 3 to obtain MVs. At the same passage,
2 million of AMCs from each amniotic membrane were
washed in PBS, treated with Trizol solution (Invitrogen,
Carlsbad, CA, USA) and stored at 80 C until use.
Isolation and Measurements of MVs
Microvesicles were obtained from the culture media of P3
AMCs cultured for a week with HG-DMEM supplemen-
ted with 10% MVs-deprived FBS, and overnight in HG-
DMEM deprived of FBS and supplemented with 0.5%
bovine serum albumin (BSA). The isolation and measure-
ments of MVs were performed as previously described by
Lange-Consiglio et al.22 Briefly, the overnight culture
media were centrifuged at 2,000g for 20 min to remove
debris, then at 100,000g (Beckman Coulter Optima L-100
K ultracentrifuge) for 1 h at 4 C. The pellet was washed
in serum-free medium 199 containing N-2-hydroxyethyl-
piperazine-N-2-ethanesulfonic acid (HEPES) 25 mM and
submitted to a second ultracentrifugation under the same
conditions. The final pellet was immediately resuspended
in HG-DMEM, and a sample of the resuspended pellet
was taken for measurement of MV size and concentration.
The remaining pellet was treated with RNase, with 800 mL
of Trizol solution, stored at 80 C, and used for RNA
extraction. Size and concentration of MVs were evaluated
by the Nanosight LM10 instrument (Nanoparticle Tracking
Analysis [NTA], Nano-Sight Ltd., Amesbuty, United King-
dom), which permits discrimination of microparticles less
than 1 mm in diameter. The software (NTA Version 2.0
analytic software) allows for the analysis of video images
of particle movement under Brownian motion and the
calculation of a diffusion coefficient, sphere equivalent,
and hydrodynamic radius of particles by using the
Strokes–Einstein equation.
RNA Isolation
Samples for RNA isolation were represented by 2 pools of
amniotic cells (eachobtainedbypooling3amnioticmembranes)
and by the 2 corresponding pools of MVs. Total RNA was
isolated from isolate MVs and from cells. Total RNA was pur-
ified by NucleoSpin1 miRNA kit (Macherey-Nagel,
Germany), following the protocol in combination with TRI-
zol1 (Invitrogen, Carlsbad, CA, USA) lysis with small and
large RNA in 1 fraction (total RNA). Concentration and quality
of RNA were determined by Agilent 2100 Bioanalyzer (Santa
Clara, CA, USA). The isolated RNAs were stored at 80 C
until use.
Library Preparation and Sequencing
Four libraries were obtained either for MVs or cells, repre-
senting 2 different isolated pools and 2 technical replicates
each. The libraries were prepared using TruSeq Small RNA
Library Preparation kits, according to manufacturer’s
instructions (Illumina). Libraries were then purified on a
Pippin Prep system (Sage Science, Beverly, MA, USA) to
recover from 125 to 167 nt fraction containing mature miR-
NAs. The quality and yield after sample preparation were
measured with an Agilent 2200 Tape Station, High Sensitiv-
ity D1000. The obtained libraries were quantified by Real
Time PCR with KAPA Library Quantification Kits (Kapa
Biosystems, Inc., Wilmington, MA, USA). Libraries were
sequenced on a single lane of Illumina Hiseq 2000 (San
Diego, CA, USA).
miRNA Data Analysis
After quality check with FastQC (http://www.bioinformatics.
babraham.ac.uk/projects/fastqc/) and trimming with Trimmo-
matic34. Illumina sequences were input to miRDeep235 for
miRNA detection and discovery. Equus caballus miRNAs
available at MirBase (http://www.mirbase.org/) were used to
accomplish known miRNA detection. Known miRNAs from
related species (sheep, cow, and goat) available at MirBase
were also input into miRDeep2 to support the individuation
of novel miRNAs. The miRDeep2 quantifier module was
used to quantify expression and retrieve counts for the
detected known and novel miRNAs. Differential expression
analyses between samples were run with the Bioconductor
edgeR package (version 2.4) (false discovery rate [FDR] <
0.000001)36. MicroRNA cluster analysis was performed with
Genesis37. Box-plot graphic was generated with BoxPlotR38.
MicroRNA target prediction and functional analysis were per-
formed by Ingenuity Pathway Analysis (IPA, Ingenuity Sys-
tem, www.ingenuity.com). Human homologous miRNAs
were analyzed with miRNA target filter (IPA) to attribute
(experimentally observed) target genes. Finally, miRNA
target mRNA and the corresponding experimental log ratios
were used for pathway analysis.
miRNA validation by quantitative polymerase chain
reaction (q-PCR)
Samples of RNA isolated from each organ were retrotran-
scribed with miScript II RT Kit following the manufacturer’s
instructions (Qiagen, Inc., Valencia, CA, USA). Quantitative
real-time reverse transcription polymerase chain reaction
(RT-PCR) was carried out on cDNAs with 7900HT Fast
Real-Time PCR System (Applied Biosystems, Carlsbad,
CA, USA). Reactions were done in 10 mL volumes containing
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0.5 mL of each forward and 0.5 mL of universal reverse primer
(Qiagen, Inc.), 4 mL cDNA, and 5 mL 2 Power SYBR1
Green PCR Master Mix (Applied Biosystems) according to
the manufacturer’s protocols. The primers used for eca-miR-
146a, eca-miR-26, and eca-miR-223 were Hs_miR-146a_1,
Hs_miR-26a_2, and Hs_miR-223_1 miScript Primer Assay
(Qiagen, Inc.), respectively. For the normalization, the refer-
ence U6 small nuclear RNA Hs_RNU6-2_11 miScript Primer
(Qiagen, Inc.) was used. Negative controls using water in
place of sample were performed alongside each reaction.
Reactions were run using the cycling parameters of 95 C for
10 min, 40 cycles of 95 C for 15 s, and 60 C for 1 min.
Relative expression levels were calculated and significance
for each treatment separately using the 2-Ct method39.
Statistical Analysis
A general linear model was used in the Bioconductor EdgeR
package to generate lists of miRNAs with statistically sig-
nificant different expression between sample groups. EdgeR
uses negative binomial-based models to variation the quad-
ratic mean–variance relationship that can be observed in
sequencing reads data and to distinguish between biological
and technical sources of variation40. Pathway analysis was
performed with the Ingenuity Pathway 198 Analysis software
(IPA, Ingenuity System, www.ingenuity.com).
Results
Cell Isolation
Cells were selected purely on their ability to adhere to plas-
tic. The initial viability of AMCs was >90% as detected by
Trypan blue exclusion. These cells show typical fibroblast-
like morphology (Fig. 1). Previous molecular biological
analyses on AMCs at P3 showed that these cells display a
typical stem cell phenotype, with the expression of markers,
such as CD29, CD44, CD106, CD105, and MHCI, but not
CD34 andMHCII. Moreover, these cells have differentiation
potential toward mesenchymal (adipogenic, chondrogenic,
and osteogenic differentiation) and ectodermic lines (neuro-
genic differentiation) as reported by Lange-Consiglio et al.33
Isolation and Measurements of MVs
The size of MVs ranged from 50 nm to 670 nm, with a mean
size of 258+ 55 nm for the 6 samples. The number of MVs
ranged from 800 to 4,700 particles/cell, with a mean value
of 2,550 + 71 particles/cell (corresponding to 540  106
particles/mL ofmedium). Previously, a study using transmis-
sion electron microscopy22 revealed the presence of variably
sized extracellular membranous vesicles budding from, or
lying near, the source cell and characterized by an
electron-lucent or moderately electron-dense content. The
size of these MVs varied from about 100 nm to 1,000 nm,
with a predominance of vesicles between 100 nm and 200 nm.
The vesicles were roughly spherical. Multivesicular bodies in
the early stages of maturation were occasionally detected.
This suggests that the production of exosomes by these cells
is less relevant than that of shedding vesicles. Because of size
and morphological characteristics, the vesicles observed were
mainly considered as shedding vesicles.
miRNA Analysis
Hiseq sequencing resulted in 184,147,508 reads with an aver-
age production of 23,018,439 reads per sample (range
between 17,251,888 and 40,351,754). About 7.34% and
56.28% of the total reads were assigned to miRNA for MVs
and cells, respectively (Table 1). In order to explore the
miRNA content in MVs and cells, bioinformatic analyses of
sequenced products were performed using miRDeep2 soft-
ware (version 2.0.0.5). In all samples tested, 1,285 known and
novel miRNA were identified and quantified. Among these
miRNAs, 401 were classified as already known eca-miRNA,
257 were found by homology with miRNAs from other spe-
cies and 627 were unknown predicted candidate miRNA
(Online Supplementary Materials S1, S2, and S3).
After applying a stringent filtering approach (FDR <
0.000001) to compare miRNA abundance in MVs and cells,
146 differentially expressed (DE) miRNAs were identified,
36 of which were known and the remaining were novel
(Online Supplementary Material S4). A tree with a clear
distinction between the MVs and cells was generated by
cluster analysis (Fig. 2). Among the known DE miRNAs
considered, 17 miRNAs showed greater expression in MVs.
A view of the normalized expression of miRNAs in MVs and
cells is reported in Fig. 3.
Three of these DE genes were validated by RT-PCR: eca-
miR-26, eca-miR-146a, and eca-miR-223 (Fig. 4). For each
test, qPCR results confirmed RNA-Seq data. Eca-miR-26,
eca-miR-146a, and eca-miR-223 showed fold change ratio
in qPCR between MVs versus cells of 0.68, 4.72, and 16.13,
respectively. Considering RNA-Seq data, eca-miR-223 was
Figure 1. Morphology of equine amniotic mesenchymal derived
cells. Magnification 20. Scale bar 20 nm.
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observed only in MVs, whereas eca-miR-26 and eca-miR-
146a showed a count ratio between MVs versus cells of 0.45
and 18.17, respectively.
Pathway Analysis of Predicted miRNA Targets
Pathways encompassing the target genes of the 36 known
miRNAs were identified. Interestingly, DE-miRNAs
Figure 2. Cluster analysis of the 146 differentially expressed (DE) miRNAs (FDR < 0.00001) microvesicles and cells. A subset of the first 60
DE microRNAs (ranked for FDR) were represented. M, microvescicle; C, cells; 1 and 2, biological replicates; a and b, technical replicates.
Table 1. Statistics of miRNA Sequencing for Microvesicles (MVs)
and Cells.
Total
Sequences
Count Reads
miRNA
% Identified
as miRNA
MVs 1a 17582945 1041770 5.92
MVs 1b 17251888 1172231 6.79
MVs 2a 20883727 1687592 8.08
MVs 2b 18795945 1605210 8.54
Cell 1a 40351754 17474694 43.31
Cell 1b 23975838 12141959 50.64
Cell 2a 21985243 14780903 67.23
Cell 2b 23320168 16591980 71.15
Total 184147508 66496339 36.11
Figure 3. Box plot showing the first 20 differentially expressed
(DE) Equus caballus known microRNAs (ranked for FDR) in micro-
vesicles (MVs; gray bar) and cells (white bar). Central lines inside
the boxes indicate median values, box width indicates 25% and 75%
quartile ranges around the median, “T” indicates the maximum and
minimum values, and black dots represent outliers. N ¼ 4 for
group. miRNAs overexpressed in MVs are given in bold.
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modulate different pathways involved in the immune
response (Table 2). The top canonical pathway, IL-6 signal-
ing, and many others, for example, the role of macrophages,
fibroblasts, and endothelial cells in rheumatoid arthritis; the
role of osteoblasts, osteoclasts, and chondrocytes in rheuma-
toid arthritis; acute phase response signaling; NF-kB signal-
ing; IL-10 signaling; p38 MAPK signaling; toll-like receptor
signaling; dendritic cell maturation; IL-8 signaling; IL-12
signaling and production in macrophages; and HMGB1 sig-
naling, are regulated by different DE-miRNAs. Among
these, some miRNAs (122, 126-3p, 132, 142-3p, 146a,
150, 22, 223, 451, and 504) were observed to be overex-
pressed in MVs whereas others (101, 125b-5p, 143, 21, 29b,
424, and 542-3p) were predominantly expressed in cells
(Fig. 5).
Discussion
In this work, we first performed miRNA sequencing of MVs
and AMCs. Secreted MVs contain a low percentage of miR-
NAs (7.3%) compared to their cells of origin. Although RNA
isolated from MVs is predominantly composed of small
RNAs, Lin et al.41 reported that also MVs isolated from
chondrocytes contain less miRNAs (6.1%) than cells, and
the majority of small RNAs are unannotated in the databases.
Moreover, library composition of small RNAs from deep
sequencing of neuronal exosomes shows that more than
90% of sequencing reads are assigned to tRNA, whereas
only about 2% are miRNAs42. The miRNA profiling of
human MSCs of liver resident stem cells (HLSCs) and their
related MVs show that, even though miRNA content is
tissue-specific, MVs of different origins clearly cluster
together, separately from cells, harboring a select pattern
of miRNAs32. In addition, MVs contain ribonucleoproteins
that are involved in the intracellular trafficking of RNA and
this suggests a dynamic regulation of RNA compartmentaliza-
tion in MVs. The Ago2 complexes, for example, selectively
associate with miRNAs in the MVs, contributing to their
stability43.
Accordingly, our results support the hypothesis that in
AMCs, miRNAs are packaged within the MVs in a regulated
manner, with an miRNA profile distinct from that of the
parent cells. We found several miRNAs enriched hundreds
or even thousands of times in MVs, whereas others had the
tendency to remain to the same level of the parent cells.
Among the more abundant miRNAs that we found in MVs,
many have been previously reported to be secreted in MVs,
as well. MiR-223, miR-142-3p, miR-451, miR-486, and
miR-142-5p were enriched in MVs secreted from HLSCs31,
whereas miR-451, miR-223, miR-144, miR-142-5p,
miR-142-3p, miR-150, miR-126a-3p, and miR-132 were
found to be prevalently present in MVs from chondrocytes41.
Some of the miRNAs, that we found to be enriched in MVs
from AMCs, were reported to be accumulated also in
exosomes, for example, mir-150, miR-125a-3p, mir-451,
mir-146a, mir-486, and miR14344,45. Previous studies indi-
cated specific loading of miRNAs into exosomes45,46.
Despite the discrepancies in their biogenesis process, it is
likely that the system to sort miRNAs in exosome is well
conserved and used to vehicle miRNAs also into MVs. It is
Figure 4. Validation of microvesicles (MVs) and cells microRNA (miRNA) expression. Three miRNAs (eca-miR-26, eca-miR-146a, and eca-
miR-223) were selected for further qPCR assays. Consistent with previous sequencing results, the expression of miR-146 and miR-223
miRNAs is higher in MVs compared to cells. miR-26 is enriched in cells. M, microvesicles; C, cells.
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noteworthy that our results are consistent with miRNA profil-
ing of MVs and cells isolated from different species and ana-
lyzed using different miRNA detection platforms. Hence, it is
unlikely that enrichment of specific miRNAs in MVs derived
from AMCs is a technical artifact. In addition, real-time PCR
validates eca-miR-26, eca-miR-146a, and eca-miR-223
expression in MVs and counterpart cells.
Microvesicles may act as mediators of cell-to-cell com-
munication through miRNA delivery32, and Mehta and Bal-
timore47 have recently reviewed the role of miRNAs in
regulating the immune system.
Our findings support the hypothesis that MVs secreted
from AMCs contain miRNAs able to modulate the immune
response. Target genes of miRNAs DE between MVs and
cells are mainly associated with the immune response: for
example, IL-6 signaling, acute-phase response signaling,
NF-kB signaling, IL-10 signaling, p38 MAPK signaling,
toll-like receptor signaling, IL-8 signaling, IL-12 signaling,
and production in macrophages. In addition, many of the
miRNAs enriched in AMC-MVs are observed to regulate the
inflammatory response. For example, overexpression of miR-
146 decreases the expression of the inflammatory cytokine
IL-6 in LPS-stimulated macrophage cells. MiR-223 can nega-
tively regulate the expression of many inflammatory genes in
macrophage cells (i.e., IL-6, IL-1b, and TNF-a)48. Exosomal
miR-146 and miR-223 are seen to contribute to cardioprotec-
tion in infarction and sepsis also in vivo49,50. Again, miR-150
decreases production of inflammatory cytokines, such as IL-2
and TNF-a, and elicits the induction of immune tolerance51;
miRNA-122 inhibits the production of cytokines in human
hepatic stellate cells52 and miR-126 promotes angiogenesis
and inhibits vascular inflammation in endothelial cells53.
Finally, other miRNAs involved in regulation of the immune
response such as miR-125b-5p, miR-143, miR-21, miR-29b,
and miR-424 are underrepresented in the MVs. Although
these miRNAs show an anti-inflammatory effect if upregu-
lated, the exact functional outcome is determined by multiple
features including the cell type and the inducing signal, which
ultimately affect the availability and ability to engage differ-
ent target mRNAs and fine tune the response54,55.
Conclusions
Our work provides a deep characterization of miRNAs present
in AMCs and their MVs. Compared to parent cells, a strong
compartmentalization of specificmiRNAs inMVs is observed.
Our study suggests a potential role of MVs as regulatory ele-
ments in cell–cell communication, through the transfer ofmiR-
NAs, and their probable involvement in the anti-inflammatory
process thatwepreviously tested in vitro on stressed tendon and
endometrial cells21,22. These results are promising for theuse of
MVs as possible future candidates in cell-free therapy but,
obviously, the work is in progress. It will be necessary to mon-
itor the ribonucleoproteins involved in the intracellular traffick-
ing of RNAs and to compare the species of miRNAs contained
in theMVsand in the cells of origin to obtain informationon the
mechanism of RNA accumulation within MVs. Moreover, it
should be demonstrated that miRNAs contained inside MVs
are transferred to target cells. This will require studying the
miRNA cargo inside the target cells to confirm the presence
Table 2. Canonical Pathway Analysis of mRNA Targets for the 36
Known Differentially Expressed miRNA (FDR < 0.000001).
Canonical Pathways
log
(P Value) z-Score
IL-6 signaling 31.30 1.121
Pancreatic adenocarcinoma signaling 30.10 1.095
Molecular mechanisms of cancer 28.80 NaN
Hepatic fibrosis/hepatic stellate cell activation 26.60 NaN
Role of macrophages, fibroblasts, and
endothelial cells in rheumatoid arthritis
26.00 NaN
p53 Signaling 23.70 0.557
Role of osteoblasts, osteoclasts, and
chondrocytes in rheumatoid arthritis
21.40 NaN
Chronic myeloid leukemia signaling 21.10 NaN
Acute phase response signaling 20.70 0.87
Glioma signaling 20.30 1.89
NF-kB signaling 19.70 0.507
Glioblastoma multiforme signaling 19.60 1.732
IL-10 signaling 19.00 NaN
p38 MAPK signaling 18.40 1.732
Toll-like receptor signaling 18.00 1.886
Dendritic cell maturation 18.00 0.539
PTEN signaling 17.20 2.2
Colorectal cancer metastasis signaling 16.90 0.169
PPAR signaling 16.70 0.408
Small cell lung cancer signaling 16.70 NaN
Prostate cancer signaling 16.60 NaN
IL-8 signaling 16.60 0.174
Melanoma signaling 16.00 NaN
Cell cycle: G1/S checkpoint regulation 15.80 1.886
Cholecystokinin/gastrin-mediated signaling 15.80 0.816
Hepatic cholestasis 15.70 NaN
Glucocorticoid receptor signaling 15.50 NaN
Aryl hydrocarbon receptor signaling 15.20 0.447
Non-small cell lung cancer signaling 15.20 1.213
Ovarian cancer signaling 14.90 NaN
Role of tissue factor in cancer 14.80 NaN
IL-12 signaling and production in
macrophages
14.80 NaN
PI3K/AKT signaling 14.60 1.279
HGF signaling 14.40 1.279
PEDF signaling 14.40 0.894
Bladder cancer signaling 14.10 NaN
EGF signaling 14.00 0.688
HMGB1 signaling 13.90 1.633
Apoptosis signaling 13.80 1.528
Myc-mediated apoptosis signaling 13.80 NaN
Note. Pathways related to inflammatory response are given in boldface. IL:
interleukin; p53: protein 53; NF-kB: nuclear factor kappa-light-chain-enhan-
cer of activated B cells; p38: protein 38; MAPK: mitogen-activated protein
kinase; PTEN: phosphatase and tensin homolog; PPAR: peroxisome prolif-
erator-activated receptor; PI3K/AKT: phosphoinositide-3-kinase/protein
kinase B; HGF: epatocyte growth factor; PEDF: pigment epithelium-derived
factor; EGF: epidermal growth factor; HMGB1: high-mobility group protein 1.
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of transferred miRNAs and to understand if these miRNAs
are functional. Last but not least, it is important to underline
that our studywas performedwith amniotic cells that represent
an alternative andpromising source ofMSCswith the appeal of
possibly producing off-the-shelf cells and cell-free products
from a biological waste, which extrafetal membranes are
considered.
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